Compare BCBP & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | PYXS |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.3M | 141.3M |
| IPO Year | 2005 | 2021 |
| Metric | BCBP | PYXS |
|---|---|---|
| Price | $8.76 | $3.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.00 | $7.00 |
| AVG Volume (30 Days) | 169.8K | ★ 1.5M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.31 | $1.03 |
| 52 Week High | $11.71 | $5.55 |
| Indicator | BCBP | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 52.25 |
| Support Level | $8.57 | $1.37 |
| Resistance Level | $10.71 | $3.40 |
| Average True Range (ATR) | 0.27 | 0.46 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 21.14 | 56.43 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.